Intracoronary ReoPro No Help at 1 Year (CME/CE)

(MedPage Today) -- For patients with an acute ST-segment elevation MI (STEMI), intracoronary administration of abciximab (ReoPro) in the catheterization lab does not improve clinical outcomes, 1-year results of the AIDA STEMI trial confirmed.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news